4-bromothiophene-2-sulfonamide | 214342-79-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-bromothiophene-2-sulfonamide
• CAS: 214342-79-7
• 化学式: C₄H₄BrNO₂S₂
• mdl: MFCD21893155
• 分子量: 242.117
• InChiKey: MZQCSQKZJCIDSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2,4-二氯苯甲酸 、 4-bromothiophene-2-sulfonamide 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-bromothiophen-2-yl)sulfonyl-2,4-dichlorobenzamide
  参考文献：
  名称：

  Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

  摘要：

  The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.041
• 作为产物：
  描述：

  4,5-二溴噻吩-2-磺酰胺 在 溶剂黄146 、 锌 作用下， 生成 4-bromothiophene-2-sulfonamide
  参考文献：
  名称：

  Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives

  摘要：

  The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.041

文献信息

• Pyridine derivatives and pharmaceutical compositions containing them
  申请人：AstraZeneca UK Limited

  公开号：US06143751A1

  公开（公告）日：2000-11-07

  Compounds of the formula (I) wherein X, R.sup.1, R.sup.2, and Ar.sup.1 as defined in the specification. The compounds are useful medicaments, particularly in the treatment of asthma or rhinitis.

  化合物的公式（I），其中X，R.sup.1，R.sup.2和Ar.sup.1如规范中定义的。这些化合物在药物中有用，特别是在治疗哮喘或鼻炎方面。
• [EN] PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE DESTINES AU TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2005058299A1

  公开（公告）日：2005-06-30

  Compounds of formula (I): Wherein: R1 is-XSO2NR6R7; wherein X is -(CH2)p - or C2-6 alkenylene; p is an integer from 0 to 6; Ar2 is a mono or bicyclic heteroaryl or a bicyclic aryl group; and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).

  公式（I）的化合物：其中：R1是-XSO2NR6R7；其中X是-(CH2)p-或C2-6烯烃基；p是从0到6的整数；Ar2是单环或双环杂芳基或双环芳基基团；以及其盐类、溶剂合物和生理功能衍生物，用于预防或治疗选择性β2-肾上腺素受体激动剂适应症的临床病症，例如哮喘或慢性阻塞性肺病（COPD）。
• Heterocycle RMB39 Modulators
  申请人：Recursion Pharmaceuticals, Inc.

  公开号：US20240092770A1

  公开（公告）日：2024-03-21

  Provided herein are compounds that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
• Acyl sulfonamide anti-proliferatives. Part 2: Activity of heterocyclic sulfonamide derivatives
  作者：Mary M. Mader、Chuan Shih、Eileen Considine、Alfonso De Dios、Cora Sue Grossman、Philip A. Hipskind、Ho-Shen Lin、Karen L. Lobb、Beatriz Lopez、José E. Lopez、Luisa M. Martin Cabrejas、Michael E. Richett、Wesley T. White、Yiu-Yin Cheung、Zhongping Huang、John E. Reilly、Sean R. Dinn

  DOI：10.1016/j.bmcl.2004.11.041

  日期：2005.2

  The anti-proliferative activity of acylated heterocyclic sulfonamides is described in Vascular Endothelial Growth Factor-dependent Human Umbilical Vascular Endothelial Cells (VEGF-HUVEC) and in HCT116 tumor cells in a soft agar diffusion assay. (C) 2004 Elsevier Ltd. All rights reserved.